Provera (Medroxyprogesterone Acetate) Dosing Recommendations
For endometrial protection in postmenopausal women on estrogen therapy, use medroxyprogesterone acetate (MPA) 2.5 mg daily for continuous combined regimens or 5-10 mg daily for 12-14 days per month for sequential regimens. 1, 2
Dosing by Clinical Indication
1. Endometrial Protection with Estrogen Therapy (Postmenopausal Women)
Sequential (Cyclic) Regimens:
- 5 mg daily for 12-14 consecutive days per month (minimum effective dose)
- 10 mg daily for 12-14 consecutive days per month (standard dose)
- Start on day 1 or day 16 of the cycle 2
- This provides adequate endometrial protection and induces withdrawal bleeding 1
Continuous Combined Regimens:
- 2.5 mg daily (minimum effective dose for endometrial protection) 1
- 5 mg daily (alternative dose) 3
- Administered continuously without interruption
- Aims to achieve amenorrhea in most women by 6 months 4
The 2011 AACE guidelines establish that both dosing strategies provide Level 1 evidence for endometrial protection 1. Sequential regimens require at least 12 days of progestogen per month to adequately protect against endometrial hyperplasia 1. Research confirms that duration matters more than dose—12-14 days is superior to shorter durations 5, 6.
2. Secondary Amenorrhea (Absent Menstrual Periods)
5-10 mg daily for 5-10 days 2
- Can start at any time if pregnancy is excluded
- 10 mg daily for 10 days is optimal for inducing secretory transformation of adequately primed endometrium
- Withdrawal bleeding typically occurs 3-7 days after stopping 2
3. Abnormal Uterine Bleeding (Dysfunctional Bleeding)
5-10 mg daily for 5-10 days 2
- Begin on calculated day 16 or 21 of menstrual cycle
- 10 mg daily for 10 days starting day 16 provides optimal secretory transformation
- Withdrawal bleeding occurs 3-7 days after discontinuation 2
- For recurrent episodes, planned menstrual cycling with MPA may be beneficial 2
4. Endometrial Hyperplasia Treatment
For hyperplasia without atypia:
- 15 mg daily (either cyclic or continuous) for 6 months 7
- Cyclic regimen shows 90% regression rate with better tolerability
- Continuous regimen shows 82.5% regression rate but higher side effects 7
For atypical hyperplasia or Grade 1 endometrial cancer (fertility preservation):
- 600 mg daily for 26 weeks (high-dose regimen) 8
- Achieves 89-93% complete response rates
- Effective for retreatment if recurrence occurs 8
5. Contraception (Depot Formulation)
Depo-Provera: 150 mg intramuscularly every 12 weeks (84 days) 9
- Highly effective with failure rate comparable to copper IUDs
- Can be given up to 5 days late (89 days maximum interval)
- Independent of user compliance between injections 9
Important Clinical Considerations
Micronized progesterone as alternative: While not the focus of this question, guidelines note that micronized progesterone 100-200 mg daily (continuous) or 200 mg daily for 12-14 days/month (sequential) provides equivalent endometrial protection 1, 3. Micronized progesterone is increasingly preferred as first-line due to lower cardiovascular and thrombotic risk 3.
Duration of therapy: Treatment should be reviewed every 3-6 months 2. Use the lowest effective dose for the shortest duration consistent with treatment goals 2.
Common pitfalls to avoid:
- Do not use progestogen for less than 12 days per month in sequential regimens—this increases hyperplasia risk 1, 10
- Do not assume all bleeding patterns are benign—perform endometrial sampling for persistent or unexpected bleeding 1
- Do not use MPA as a pregnancy test—confirm pregnancy status before initiating therapy 2
Side effects: Expect premenstrual-like symptoms (mood changes, bloating, fluid retention), breakthrough bleeding with continuous regimens, and potential weight gain 2. Switching progestogen types may reduce symptoms 1.